Significant Insider buy of Idera Pharmaceuticals (IDRA) Shares Breaks neutral Trend of Last Quarter

Monday, October 30, 2017 10:15 PM ET

Significant Insider buy of Idera Pharmaceuticals (IDRA) Shares Breaks neutral Trend of Last Quarter

Significant insider buying activity was revealed in Idera Pharmaceuticals shares in a form 4 document filed with the SEC today, showing — Baker Bros Advisors Lp, Director — purchased 8,000,000 shares in the company having a net market value of approximately $12,000,000. This is the first insider buy/sell trade in the past 90 days.

Idera Pharmaceuticals level of buy-sell trading activity is close to the 184 member peer company average. The Biotechnology & Medical Research peer group saw 208 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares per buy/sell trade transacted by Idera Pharmaceuticals insiders is higher. Within the peer group there were 7,794,256 shares purchased and 51,306,345 shares sold with company insiders selling 209,193 shares on average.

The data obtained in evaluating and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.